Kristen B. Slaoui, PhD

Kristen B. Slaoui, PhD has been the Chief Corporate Development Officer at Galderma, the world’s largest independent global dermatology company, since 2020.

Since joining Galderma, she oversaw several significant transactions including the acquisition of Alastin Skincare in 2021, adding to Galderma’s premium portfolio. Prior to this role, she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long-acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. She joined GSK’s Business Development team in 2006 and held various roles of increasing seniority, and executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009 (where she subsequently served as VP and Head of Business Development & Licensing), participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her PhD in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship at the University of Washington in Seattle, WA.